Mice with Mutations in the HPA-System as Models for Symptoms of Depression

Biological Psychiatry

Volumn 59, Issue 12, 2006, Pages 1104-1115

  Müller, Marianne B ^a   Holsboer, Florian ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

Author keywords

CRH; Depression; epigenetic programming; mouse mutants; stress hormones

Indexed keywords

ARGIPRESSIN; CORTICOSTERONE; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; CORTICOTROPIN RELEASING FACTOR RECEPTOR 2; GLUCOCORTICOID RECEPTOR; MUTANT PROTEIN; SEROTONIN; VASOPRESSIN;

ANIMAL BEHAVIOR; ANXIETY; ATROPHY; DENTATE GYRUS; DEPRESSION; DNA POLYMORPHISM; ENVIRONMENTAL FACTOR; EPIGENETICS; GENE ACTIVITY; GENE FUNCTION; GENE INACTIVATION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC ENGINEERING; GENETIC HETEROGENEITY; GENOME ANALYSIS; HIPPOCAMPUS; HORMONE RESPONSE; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MOUSE MUTANT; NERVOUS SYSTEM DEVELOPMENT; NEUROENDOCRINE SYSTEM; NEUROTRANSMISSION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; STRESS; SYMPTOM; TRANSGENIC MOUSE;

ANIMALS; DEPRESSIVE DISORDER; DISEASE MODELS, ANIMAL; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MICE; MICE, TRANSGENIC; MUTATION; PITUITARY-ADRENAL SYSTEM;

EID: 33745192045     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2006.02.008     Document Type: Review

References (132)

1. Almeida O.F., Conde G.L., Chrochemore C., Demeneix B.A., Fischer D., Hassan A.H., et al. Subtle shifts in the ratio between pro- and antiapoptotic molecules after activation of corticosteroid receptors decide neuronal fate. FASEB J 14 (2000) 779-790
2. 1b receptors reverses stress-induced suppression of neurogenesis in a mouse model of depression. Mol Psychiatry 9 (2004) 278-286
3. 7 serotonin receptor and transcription factor NGFI-A in the fetal guinea-pig limbic system. influence of GCs. J Physiol 555 (2004) 659-670
4. Bale T.L., Contarino A., Smith G.W., Chan R., Gold L.H., Sawchenko P.E., et al. Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress. Nature Genet 24 (2000) 410-414
5. Bale T.L., Picetti R., Contarino A., Koob G.F., Vale W.W., and Lee K.F. Mice deficient for both corticotropin-releasing factor receptor 1 (CRFR1) and CRFR2 have an impaired stress response and display sexually dichotomous anxiety-like behavior. J Neurosci 22 (2002) 193-199
6. Bale T.L., and Vale W.W. Increased depression-like behaviors in corticotropin-releasing factor receptor-2-deficient mice. sexually dichotomous responses. J Neurosci 23 (2003) 5295-5301
7. Bale T.L., and Vale W.W. CRF and CRF receptors. Role in stress responsivity and other behaviors. Ann Rev Pharmacol Toxicol 44 (2004) 525-557
8. Barden N., Stec I.S., Montkowski A., Holsboer F., and Reul J.M. Endocrine profile and neuroendocrine challenge tests in transgenic mice expressing antisense RNA against the glucocorticoid receptor. Neuroendocrinology 66 (1997) 212-220
9. Bayatti N., Hermann H., Lutz B., and Behl C. Corticotropin-releasing hormone-mediated induction of intracellular signaling pathways and brain-derived neurotrophic factor expression is inhibited by the activation of the endocannabinoid system. Endocrinology 146 (2005) 1205-1213
10. Beato M., Herrlich P., and Schütz G. Steroid hormone receptors. many actors in search of a plot. Cell 83 (1995) 851-857
11. Belanoff J.K., Rothschild A.J., Cassidy F., De Battista C., Baulieu E.E., Schold C., and Schatzberg A.F. An open label trial of C-1073 (mifepristone) for psychotic major depression. Biol Psychiatry 52 (2002) 386-392
12. Bielsky I.F., Hu S.B., Szegdal K.L., Westphal H., and Young L.J. Profound impairment in social recognition and reduction in anxiety-like behavior in vasopressin via receptor knockout mice. Neuropsychopharmacology 29 (2004) 483-493
13. Binder E.B., Salyakina D., Lichtner P., Wochnik G.M., Ising M., Pütz B., et al. Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat Genet (2004) 1-7 (online Publication)
14. Boyle M.P., Brewer J.A., Funatsu M., Wozniak D.F., Tsien J.Z., Izumi Y., and Muglia L.J. Acquired deficit of forebrain glucocorticoid receptor produces depression-like changes in adrenal axis regulation and behavior. Proc Acad Natl Sci USA 102 (2005) 473-478
15. Brady L.S., Whitifield Jr. H.J., Fox R.J., Gold P.W., and Herkenham M. Long-term antidepressant administration alters corticotrophin-releasing hormone, tyrosine hydroxylase, and mineralocorticoid receptor gene expression in the rat brain. J Clin Invest 87 (1991) 831-837
16. Cole T.J., Myles K., Purton J.F., Brereton P.S., Solomon N.M., Godfrey D.I., and Funder J.W. GR KO mice express an aberrant dexamethasone-binding glucocorticoid receptor, but are profoundly glucocorticoid resistant. Mol Cell Endocrinol 173 (2001) 193-202
17. Cole T.J., Blendy J.A., Monaghan A.P., Krieglstein K., Schmid W., Aguzzi A., Fantuzzi G., Hummler E., Unsicker K., and Schütz G. Targeted disruption of the glucocorticoid receptor gene blocks adrenergic chromaffin cell development and severely retards lung maturation. Genes Dev 9 (1995) 1608-1621
18. Coplan J.D., Andrews M.W., Rosenblum L.A., Owens M.J., Friedman S., Gorman J.M., and Nemeroff C.B. Persistent elevations of cerebrospinal fluid concentrations of corticotrophin-releasing factor in adult nonhuman primates exposed to early-life stressors. Implications for the pathophysiology of mood and anxiety disorders. Neurobiology 93 (1996) 1619-1623
19. Coste S.C., Kesterson R.A., Heldwein K.A., Stevens S.L., Heard A.D., Hollis J.H., et al. Abnormal adaptations to stress and impaired cardiovascular function in mice lacking corticotropin-releasing hormone receptor-2. Nat Genet 24 (2000) 403-409
20. Crabbe J.C., Wahlsten D., and Dudek B.C. Genetics of mouse behavior. interaction with laboratory environment. Science 284 (1999) 1670-1672
21. Dirks A., Groenink L., Bouwknecht J.A., Hijzen T.H., van der Gugten J., Ronken E., et al. Overexpression of corticotropin-releasing hormone in transgenic mice and chronic stress-like autonomic and physiological alterations. Eur J Neurosci 16 (2002) 1751-1760
22. Dirks A., Groenink L., Schipholt M.I., van der Gugten J., Hijzen T.H., Geyer M.A., and Olivier B. Reduced startle reactivity and plasticity in transgenic mice overexpressing corticotropin-releasing hormone. Biol Psychiatry 51 (2002) 583-590
23. Dunn A.J., and Berridge C.W. Physiological and behavioral responses to corticotropin-releasing factor administration. is CRF a mediator of anxiety or stress responses?. Brain Res Rev 15 (1990) 71-100
24. Dunn A.J., and Swiergiel A.H. Behavioral responses to stress are intact in CRF-deficient mice. Brain Res 845 (1999) 14-20
25. Fagiolini A., and Kupfer D.J. Is treatment-resistant depression a unique subtype of depression?. Biol Psychiatry 54 (2003) 640-648
26. Farisse J., Boulenuez P., Semont A., Hery F., Barden N., Faudon M., and Hery M. Regional serotonin metabolism under basal and restraint stress conditions in the brain of transgenic mice with impaired glucocorticoid receptor function. Neuroendocrinology 70 (1999) 413-421
27. van Gaalen M.M., Stenzel-Poore M.P., Holsboer F., and Steckler T. Effects of transgenic overproduction of CRH on anxiety-like behaviour. Eur J Neurosci 15 (2002) 2007-2015
28. Gass P., Kretz O., Wolfer D.P., Berger S., Tronche F., Reichardt H.M., et al. Genetic disruption of mineralocorticoid receptor leads to impaired neurogenesis and granule cell degeneration in the hippocampus of adult mice. EMBO Reports 1 (2000) 447-451
29. Geyer M.A., and Markou A. The role of preclinical models in the development of psychotropic drugs. In: Nemeroff C.B. (Ed). Neuropsychopharmacology. The fifth generation of progress. (2002), Lippincott Williams and Wilkins, Philadelphia 445-455
30. Givalois L., Arancibia S., Alonso G., and Tapia-Arancibia L. Expression of brain-derived neurotrophic factor and its receptors in the median eminence cells with sensitivity to stress. Endocrinology 145 (2004) 4737-4747
31. 1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders. Proc Acad Natl Sci 99 (2002) 6370-6375
32. Griebel G., Stemmelin J., Gal C.S., and Soubrie P. Non-peptide vasopressin V1b receptor antagonists as potential drugs for the treatment of stress-related disorders. Curr Pharmaceutical Design 11 (2005) 1549-1559
33. Groenink L., Dirks A., Verdouw P.M., Schipholt M.I., Veening J.G., van der Gugten J., and Olivier B. HPA axis dysregulation in mice overexpressing corticotropin releasing hormone. Biol Psychiatry 51 (2002) 875-881
34. Groenink L., Pattij T., De Jongh R., van der Gugten J., Oosting R.S., Dirks A., and Olivier B. 5-HT1A receptor knockout mice and mice overexpressing corticotropin-releasing hormone in models of anxiety. Eur J Pharmacol 463 (2003) 185-197
35. 1b receptor ligands for pharmacological, functional and structural investigations. J Neuroendocrinol 16 (2004) 356-361
36. Heim C., and Nemeroff C.B. The role of childhood trauma in the neurobiology of mood and anxiety disorders. preclinical and clinical studies. Biol Psychiatry 49 (2001) 1023-1039
37. Heinrichs S.C., Lapsansky J., Lovenberg T.W., De Souza E.B., and Chalmers D.T. Corticotropin-releasing factor CRF1, but not CRF2, receptors mediate anxiogenic-like behavior. Regul Pept 71 (1997) 15-21
38. Heinrichs S.C., Min H., Tamraz S., Carmouche M., Boehme S.A., and Vale W.W. Anti-sexual and anxiogenic behavioral consequences of corticotropin-releasing factor overexpression are centrally mediated. Psychoneuroendocrinology 22 (1997) 215-224
39. Hökfelt T., Bartfai T., and Bloom F. Neuropeptides. opportunities for drug discovery. Lancet Neurol 2 (2003) 463-472
40. Holsboer F., Gerken A., Steiger A., Benkert O., Müller O.A., and Stalla G.K. Corticotropin-releasing-factor induced pituitary-adrenal response in depression. Lancet 1 (1984) 55
41. Holsboer F. The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety. J Psychiatr Res 33 (1999) 181-214
42. Holsboer F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 23 (2000) 477-501
43. Holsboer F., and Barden N. Antidepressants and hypothalamic-pituitary-adrenocortical regulation. Endocr Rev 17 (1996) 187-205
44. Holsboer F., Lauer C.J., Schreiber W., and Krieg J.C. Altered hypothalamic-pituitary-adrenocortical regulation in healthy subjects at high familial risk for affective disorders. Neuroendocrinology 62 (1995) 340-347
45. Hsu S.Y., and Hsueh A.J. Human stresscopin and stresscopin-related peptide are selective ligands for the type 2 corticotropin-releasing hormone receptor. Nat Med 7 (2001) 605-611
46. Huang G.J., and Herbert J. Serotonin modulates the suppressive effects of corticosterone on proliferating progenitor cells in the dentate gyrus of the hippocampus in the adult rat. Neuropsychopharmacology 30 (2005) 231-241
47. Itoi K., Jiang Y.-Q., Iwasaki Y., and Watson S.J. Regulatory mechanisms of corticotropin-releasing hormone and vasopressin gene expression in the hypothalamus. J Neuroendocrinol 16 (2004) 348-355
48. Ivy A.S., Rodriguez F.G., Garcia C., Chen M.J., and Russo-Neustadt A.A. Noradrenergic and serotonergic blockade inhibits BDNF mRNA activation following exercise and antidepressant. Pharmacol Biochem Behav 75 (2003) 81-88
49. Jacobson L., Muglia L., Weninger S.C., Pacak K., and Majzoub J. CRH deficiency impairs but does not block pituitary-adrenal responses to diverse stressors. Neuroendocrinology 71 (2000) 79-87
50. Jang K.L., Livesley W.J., Taylor S., Stein M.B., and Moon E.C. Heritability of individual depressive symptoms. J Affective Disorders 80 (2004) 125-133
51. Karten Y.J.G., Nair S.M., van Essen L., Sibug R., and Joëls M. Long-term exposure to high corticosterone levels attenuates serotonin responses in rat hippocampal CA1 neurons. Proc Acad Natl Sci USA 96 (1999) 13456-13461
52. Kaufer D., Ogle W.O., Pincus Z.S., Clark K.L., Nicholas A.C., Dinkel K.M., et al. Restructuring the neuronal stress response with anti-glucocorticoid gene delivery. Nat Neurosci 7 (2004) 947-953
53. Keck M.E., Holsboer F., and Müller M.B. Mouse mutants for the study of corticotropin-releasing hormone receptor function. development of novel treatment strategies for mood disorders. Ann NY Acad Sci 1018 (2004) 445-457
54. Keck M.E., Ohl F., Holsboer F., and Müller M.B. Listening to mutant mice. a spotlight on the role of CRF/CRF receptor systems in affective disorders. Neurosci Biobehav Rev 29 (2005) 867-889
55. Kessler R.C., Berglund P., Demler O., Jin R., Koretz D., Merikangas K.R., et al. The epidemiology of major depressive disorder. results from the national comorbidity survey replication (NCS-R). J.A.M.A. 289 (2003) 3095-3105
56. Kishimoto T., Radulovic J., Radulovic M., Lin C.R., Schrick C., Hooshmand F., et al. Deletion of CRHR2 reveals an anxiolytic role for corticotropin-releasing hormone receptor-2. Nat Genet 24 (2000) 415-419
57. Klein R., Conway D., Parada L.F., and Barbacid M. The trkB tyrosine protein kinase gene codes for a second neurogenic receptor that lacks the catalytic kinase domain. Cell 61 (1990) 647-656
58. de Kloet E.R., Joëls M., and Holsboer F. Stress and the brain. From adaptation to disease. Nature Rev Neurosci 6 (2005) 463-475
59. de Kloet E.R., Vreugdenhil E., Oitzl M.S., and Joëls M. Brain corticosteroid receptor balance in health and disease. Endocr Rev 19 (1998) 269-301
60. Kunugi H., Ida I., Owashi T., Kimura M., Inoue Y., Nakagawa S., et al. Assessment of the dexamethasone/CRH test as a state-dependent marker for hypothalamic-pituitary-adrenal (HPA) axis abnormalities in major depressive episode. A Multicenter Study. Neuropsychopharmacology (2005) 1-9 (online publication)
61. Kuwahara S., Arima H., Banno R., Sato I., Kondo N., and Oiso Y. Regulation of vasopressin gene expression by cAMP and glucocorticoids in parvocellular neurons of the paraventricular nucleus in rat hypothalamic organotypic cultures. J Neurosci 23 (2003) 10231-10237
62. Landgraf R., Gerstberger R., Montkowski A., Probst J.C., Wotjak C.T., Holsboer F., and Engelmann M. V1 vasopressin receptor antisense oligodeoxynucleotide into septum reduces vasopressin binding, social discrimination abilities, and anxiety-related behavior in rats. J Neurosci 15 (1995) 4250-4258
63. 7 receptor. Brain Res Dev Brain Res 139 (2002) 199-203
64. Levine S. The ontogeny of the hypothalamic-pituitary-adrenal axis. The influence of maternal factors. Ann NY Acad Sci 746 (1994) 275-293
65. Lewis K., Li C., Perrin M., Blount A., Kunitake K., Donaldson C., et al. Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc Acad Natl Sci 98 (2001) 7570-7575
66. Liebsch G., Landgraf R., Gerstberger R., Probst J.C., Wotjak C.T., Engelmann M., et al. Chronic infusion of a CRH1 receptor antisense oligodeoxynucleotide into the central nucleus of the amygdala reduced anxiety-related behavior in socially defeated rats. Regul Pept 59 (1995) 229-239
67. 1A, glucocorticoid, and mineralocorticoid receptor in rat and human hippocampus. implications for the neurobiology of depression. Biol Psychiatry 43 (1998) 547-573
68. Maccarrone G., Birg I., Malisch E., Rosenhagen M.C., Ditzen C., Chakel J.A., et al. In-depth analysis of the human CSF Proteome using protein prefractionation. Clin Proteomics 1 (2005) 333-364
69. Mamourias L.A., Blue M.E., Siuciak J.A., and Altar C.A. Brain-derived neurotrophic factor promotes the survival and sprouting of serotonergic axons in rat brain. J Neurosci 15 (1995) 7929-7939
70. McCormick J.A., Lyons V., Jacobson M.D., Noble J., Diorio J., Nyirenda M., et al. 5'Heterogeneity of glucocorticoid receptor messenger RNA is tissue specific. differential regulation of variant transcripts by early life events. Mol Endocrinol 14 (2000) 506-517
71. McEwen B.S. Invited review: estrogens effects on the brain: multiple sites and molecular mechanisms. J Appl Physiol 91 (2001) 2785-2801
72. Meaney M.J. Maternal care, gene expression, and the transmission of individual differences in stress reactivity across generations. Annu Rev Neurosci 24 (2001) 1161-1192
73. Modell S., Yassouridis A., Huber J., and Holsboer F. Corticosteroid receptor function is decreased in depressed patients. Neuroendocrinology 65 (1997) 216-222
74. Modell S., Lauer C.J., Schreiber W., Huber J., Krieg J.C., and Holsboer F. Hormonal response pattern in the combined DEX-CRH test is stable over time in subjects at high familiar risk for affective disorders. Neuropsychopharmacology 18 (1998) 253-262
75. Montkowski A., Barden N., Wotjak C., Stec I., Ganster J., Meaney M., et al. Long-term antidepressant treatment reduces behavioural deficits in transgenic mice with impaired glucocorticoid receptor function. J Neuroendocrinol 7 (1995) 841-845
76. Muglia L., Jacobson L., Dikkes P., and Majzoub J.A. Corticotropin-releasing hormone deficiency reveals major fetal but not adult glucocorticoid need. Nature 373 (1995) 427-432
77. Müller M.B., Landgraf R., Sillaber I., Kresse A.E., Keck M.E., Zimmermann S., et al. Selective activation of the hypothalamic vasopressinergic system in mice deficient for the corticotropin-releasing hormone receptor 1 is dependent on glucocorticoids. Endocrinology 141 (2000) 4262-4269
78. Müller M.B., Zimmermann S., Sillaber I., Hagemeyer T.P., Deussing J.M., Timpl P., et al. Limbic corticotropin-releasing hormone receptor 1 mediates anxiety-related behavior and hormonal adaptation to stress. Nature Neurosci 6 (2003) 1100-1107
79. Müller M.B., and Keck M.E. Genetically engineered mice for studies of stress-related clinical conditions. J Psychiatr Res 36 (2002) 53-76
80. Müller M.B., Lucassen P.J., Yassouridis A., Hoogendijk W.J.G., Holsboer F., and Swaab D.F. Neither major depression nor glucocorticoid treatment affects the cellular integrity of the human hippocampus. Eur J Neurosci 14 (2001) 1603-1612
81. Murgatroyd C., Wigger A., Frank E., Singewald N., Bunck M., Holsboer F., et al. Impaired repression at a vasopressin promoter polymorphism underlies overexpression of vasopressin in a rat model of trait anxiety. J Neurosci 24 (2004) 7762-7770
82. Neumeister A., Wood S., Bonne O., Nugent A.C., Luckenbaugh D.A., Young T., et al. Reduced hippocampal volume in unmedicated, remitted patients with major depression versus control subjects. Biol Psychiatry 57 (2005) 935-937
83. Nibuya M., Morinobu S., and Duman R.S. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci 15 (1995) 7539-7547
84. Oitzl M.S., de Kloet E.R., Joëls M., Schmid W., and Cole T.J. Spatial learning deficits in mice with a targeted glucocoeticoid receptor gene disruption. Eur J Neurosci 9 (1997) 2284-2296
85. Oitzl M.S., Reichardt H.M., Joels M., and de Kloet E.R. Point mutation in the mouse glucocorticoid receptor preventing DNA binding impairs spatial memory. Proc Acad Natl Sci USA 98 (2001) 12790-12795
86. Oshima A., Flachskamm C., Reul J.M.H.M., Holsboer F., and Linthorst A.C.E. Altered serotonergic neurotransmission but normal hypothalamic-pituitary-adrenocortical axis activity in mice chronically treated with the corticotropin-releasing hormone receptor type I antagonist NBI 30775. Neuropsychopharmacology 28 (2003) 2148-2159
87. Owens M.J., and Nemeroff C.B. Physiology and pharmacology of corticotropin releasing factor. Pharmacol Rev 43 (1991) 425-473
88. Patel P.D., Lopez J.F., Lyons D.M., Burks S., Wallace M., and Schatzberg A.F. Glucocorticoid and mineralocorticoid receptor mRNA expression in squirrel monkey brain. J Psychiatr Res 34 (2000) 383-392
89. Pelleymounter M.A., Joppa M., Ling N., and Foster A.C. Behavioral and neuroendocrine effects of the selective CRF2 receptor agonists urocortin II and urocortin III. Peptides 25 (2004) 659-666
90. Peñalva R.G., Flachskamm C., Zimmermann S., Wurst W., Holsboer F., Reul J.M.H.M., and Linthorst A.C.E. Corticotropin-releasing hormone receptor type 1-deficiency enhances hippocampal serotonergic neurotransmission. an in vivo microdialysis study in mutant mice. Neuroscience 109 (2002) 253-266
91. Pepin M.C., Pothier F., and Barden N. Impaired type II glucocorticoid-receptor function in mice bearing antisense RNA transgene. Nature 355 (1992) 725-728
92. Pepin M.C., Pothier F., and Barden N. Antidepressant drug action in a transgenic mouse model of the endocrine changes seen in depression. Mol Pharmacol 42 (1992) 991-995
93. Preil J., Müller M.B., Gesing A., Reul J.M.H.M., Sillaber I., van Gaalen M., et al. Regulation of the hypothalamic-pituitary-adrenocortical system in mice deficient for CRH receptors 1 and 2. Endocrinology 142 (2001) 4946-4955
94. Rattiner L.M., Davis M., French C.T., and Ressler K.J. Brain-derived neurotrophic factor and tyrosine kinase receptor B involvement in amygdala-dependent fear conditioning. J Neurosci 24 (2004) 4796-4806
95. Raadsheer F.C., Hoogendijk W.J.G., Stam F.C., Tilders F.J.H., and Swaab D.F. Increased number of corticotropin-releasing hormone expressing neurons in the hypothalamic paraventricular nucleus of depressed patients. Neuroendocrinology 60 (1994) 436-444
96. Refojo D., Echenique C., Müller M.B., Reul J.M., Deussing J.M., Wurst W., et al. Corticotropin-releasing hormone activates ERK1/2 MAPK in specific brain areas. Proc Acad Natl Sci USA 102 (2005) 6183-6188
97. Reichhardt H.M., Kaestner K.H., Tuckermann J., Kretz O., Wessely O., Bock R., et al. DNA binding of the glucocorticoid receptor is not essential for survival. Cell 93 (1998) 531-541
98. Reichardt H.M., Umland T., Bauer A., Kretz O., and Schutz G. Mice with an increased glucocorticoid receptor gene dosage show enhanced resistance to stress and endotoxic shock. Mol Cell Biol 20 (2000) 9009-9017
99. Reul J.M., Gesing A., Droste S., Stec I.S., Weber A., Bachmann C., Bilang-Bleuel A., Holsboer F., and Linthorst A.C. The brain mineralocorticoid receptor. greedy for ligand, mysterious in function. Eur J Pharmacol 405 (2000) 235-249
100. Reul J.M.H.M., Labeur M.S., Grigoriadis D.E., De Souza E.B., and Holsboer F. Hypothalamic-pituitary-adrenocortical axis changes in the rat after long-term treatment with the reversible monoamine oxidase-A inhibitor moclobemide. Neuroendocrinology 60 (1994) 509-519
101. Reul J.M.H.M., Stec I., Söder M., and Holsboer F. Chronic treatment of rats with the antidepressant amitriptyline attenuates the activity of the hypothalamic-pituitary-adrenocortical system. Endocrinology 133 (1993) 312-320
102. Reyes T.M., Lewis K., Perrin M.H., Kunitake K.S., Vaughan J., Arias C.A., et al. Urocortin II. A member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. Proc Natl Acad Sci USA 98 (2001) 2843-2848
103. Ridder S., Chourbaji S., Hellweg R., Urani A., Zacher C., Schmid W., et al. Mice with genetically altered glucocorticoid receptor expression show altered sensitivity for stress-induced depressive reactions. J Neurosci 25 (2005) 6243-6250
104. Saarelainen T., Hendolin P., Lucas G., Koponen E., Sairanen M., MacDonald E., et al. Activation of the trkB neurotrophin receptor is induced by antidepressant drugs and is required for antidepressant-induced behavioral effects. J Neurosci 23 (2003) 349-357
105. Santarelli L., Saxe M., Gross C., Surget A., Battaglia F., Dulawa S., et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 301 (2003) 805-809
106. Schaaf M.J., Hoetelmans R.W., de Kloet E.R., and Vreugdenhil E. Corticosterone regulates expression of BDNF and trkB but not NT-3 and trkC mRNA in the rat hippocampus. J Neurosci Res 48 (1997) 334-341
107. Smith M.A., Makino S., Kvetnansky R., and Post R.M. Stress alters the express of brain-derived neurotrophic factor and neurotrophin-3 mRNAs in the hippocampus. J Neurosci 15 (1995) 1768-1777
108. Smith G.W., Aubry J.M., Dellu F., Contarino A., Bilezikijan L.M., Gold L.H., et al. Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development. Neuron 20 (1998) 1093-1102
109. Stec I., Barden N., Reul J.M., and Holsboer F. Dexamethasone non-suppression in transgenic mice expressing antisense RNA to the glucocorticoid receptor. J Psychiatr Res 28 (1994) 1-5
110. Steckler T., and Holsboer F. Enhanced conditioned approach responses in transgenic mice with impaired glucocorticoid receptor function. Behav Brain Res 102 (1999) 151-163
111. Steckler T., Rammes G., Sauvage M., van Gaalen M.M., Weis C., Zieglgänsberger W., and Holsboer F. Effects of the monoamine oxidase A inhibitor moclobemide on hippocampal long-term plasticity in GR-impaired transgenic mice. J Psychiatr Res 35 (2001) 29-42
112. Szyf M. Towards a pharmacology of DNA methylation. Trends Pharmacol 22 (2001) 350-354
113. Stenzel-Poore M.P., Cameron V.A., Vaughan J., Sawchenko P.E., and Vale W. Development of Cushing's syndrome in corticotropin-releasing factor transgenic mice. Endocrinology 130 (1992) 3378-3386
114. Stenzel-Poore M.P., Heinrichs S.C., Rivest S., Koob G.F., and Vale W.W. Overproduction of corticotropin-releasing factor in transgenic mice. a genetic model of anxiogenic behavior. J Neurosci 14 (1994) 2579-2584
115. Thoenen H. Neurotrophins and neuronal plasticity. Science 270 (1995) 593-598
116. Timpl P., Spanagel R., Sillaber I., Kresse A., Reul J.M.H.M., Stalla G.K., et al. Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor 1. Nat Genet 19 (1998) 162-166
117. Trapp T., Rupprecht R., Castren M., Reul J.M., and Holsboer F. Heterodimerization between mineralocorticoid and glucocorticoid receptor. a new principle of glucocorticoid action in the CNS. Neuron 13 (1994) 1457-1462
118. Tronche F., Kellendonk C., Kretz O., Gass P., Anlag K., Orban P.C., et al. Disruption of the glucocorticoid receptor gene in the nervous system results in reduced anxiety. Nat Genet 23 (1999) 99-103
119. Vaughan J., Donaldson C., Bittencourt J., Perrin M.H., Lewis K., Sutton S., et al. Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature 378 (1995) 287-292
120. Venihaki M., and Majzoub J. Lessons from CRH knockout mice. Neuropeptides 36 (2002) 96-102
121. Vetter D.E., Li C., Zhao L., Contarino A., Liberman M.C., Smith G.W., et al. Urocortin-deficient mice show hearing impairment and increased anxiety-like behavior. Nat Genet 31 (2002) 363-369
122. Videbeck P., and Ravnkilde B. Hippocampal volume and depression. a meta-analysis of MRI studies. Am J Psychiatry 161 (2004) 1957-1966
123. von Bardeleben U., Holsboer F., Stalla G.K., and Müller O.A. Combined adminstration of human corticotropin-releasing factor and lysine vasopressin induces cortisol escape from dexamethasone suppression in healthy subjects. Life Sci 37 (1985) 1613-1618
124. Wang X., Su H., Copenhagen L.D., Vaishnav S., Pieri F., Do Shope C., et al. Urocortin-deficient mice display normal stress-induced anxiety behavior and autonomic control but an impaired acoustic startle response. Mol Cell Biol 22 (2002) 6605-6610
125. Weaver I.C.G., Cervoni N., Champagne F.A., D'Alessio A.C., Sharma S., Seckl J.R., et al. Epigenetic programming by maternal behavior. Nat Neurosci 7 (2004) 847-854
126. Wei Q., Lu X.Y., Liu L., Schafer G., Shieh K.R., Burke S., et al. Glucocorticoid receptor overexpression in forebrain. a mouse model of increased emotional lability. Proc Natl Acad Sci USA 101 (2004) 11851-11856
127. Weninger S.C., Dunn A.J., Muglia L.J., Dikkes P., Miczek K.A., Swiergiel A.H., et al. Stress-induced behaviors require the corticotropin-releasing hormone (CRH) receptor, but not CRH. Proc Natl Acad Sci USA 96 (1999) 8283-8288
128. Wersinger S.R., Ginns E.I., O'Carroll A.M., Lolait S.J., and Young W.S. Vasopressin V1b receptor knockout reduces aggressive behavior in male mice. Mol Psychiatry 7 (2002) 975-984
129. Wigger A., Sánchez M.M., Mathys K.C., Ebner K., Liu D., Kresse A., et al. Alterations in central neuropeptide expression, release, and receptor binding in rats bred for high anxiety. critical role of vasopressin. Neuropsychopharmacology 29 (2004) 1-14
130. Yehuda R. Post-traumatic stress disorder. N Engl J Med 346 (2002) 108-114
131. Zhao R., Davey M., Hsu Y.C., Kaplanek P., Tong A., Parsons A.B., et al. Navigating the chaperone network. An integrative map of physical and genetic interactions mediated by the Hsp90 chaperone. Cell 120 (2005) 715-727
132. Zobel A.W., Nickel T., Künzel H.E., Ackl N., Sonntag A., Ising M., and Holsboer F. Effects of the high-affinity corticotropin-releasing hormone receptor antagonist R121919 in major depression. the first 20 patients treated. J Psychiatr Res 34 (2000) 171-181